Benzinga | Aug 9, 2021 08:09AM EDT

Guggenheim Downgrades Intersect ENT to Neutral, Announces $28.25 Price Target

Guggenheim analyst Christopher Pasquale downgrades Intersect ENT (NASDAQ:XENT) from Buy to Neutral and announces $28.25 price target.